Italy authorizes a study of heparin use in patients with COVID-19: Recently it was disclosed that the Italian Medicines Agency (AIFA) authorized to initiate a multicenter study with the drug heparin, which mainly works as a low molecular weight anticoagulant, for the treatment of patients with a moderate or severe clinical picture of COVID coronavirus. COVID-19.
Italy authorizes a study of heparin
This study seeks to evaluate the safety and efficacy of this drug, which will be administered in different doses, to improve the course of the disease.
The medication is provided free of charge to 14 Italian centers participating in the study, involving a total of 300 patients, who will receive enoxaparin biosimilar for subcutaneous injection.
What is enoxaparin?
The enoxaparin sodium is low molecular weight heparin with high action antithrombotic that makes today, one of the anticoagulants most used for prevention and therapy of the venous and arterial thrombosis in patients undergoing surgery or bedridden.
The study will be coordinated by Pierluigi Viale, Professor of Infectious Diseases of the University of Bologna and Director of the Operational Infectious Disease Unit of the Hospital Sant’Orsola-Malpighi.
The experts point out that alterations of coagulation and thrombotic complications in patients coronavirus Covid-19 play an important role in terms of incidence and clinical relevance, representing one of the most important variables associated with mortality from this disease.
Is the WHO recommend heparin?
In January, the World Health Organization (WHO) recommended preventing venous thromboembolism in subjects infected with SARS-CoV-2 by resorting to subcutaneous administration of heparin, preferably with low molecular weight.
This idea gave rise to an experiment also in Italy through the use, for therapeutic purposes, of a medium-high dose of medication.